Vera Therapeutics Inc Cl A (VERA)

$32.28 +1.02 (3.25%)
Market Cap 2.33B
Revenue (ttm) 0.00
Net Income (ttm) -299.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 1,288,400
Avg Vol 2,187,040
Day's Range N/A - N/A
Shares Out 72.06M
Stochastic %K 74%
Beta 0.92
Analysts Strong Sell
Price Target $77.28

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 770 0077
Website: veratx.com
Address:
2000 Sierra Point Parkway, Suite 1200, Brisbane, United States
AgnesGregory654
AgnesGregory654 Aug. 24 at 9:18 AM
$VERA $WFC $HONA $ALB $ACI VERA advances autoimmune therapies, Wells Fargo benefits from banking activity and net-interest trends, HONA remains speculative, Albemarle remains tied to lithium prices and battery demand, and Albertsons benefits from grocery spending. I'm watching clinical data, credit conditions, lithium prices, and consumer volumes.
0 · Reply
philosophernutz
philosophernutz Aug. 24 at 1:05 AM
$VERA we need the data to drop to get some real traction.
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:33 AM
$VERA And also, do not forget $CRNX because while that buyout at eighty five dollars cash was awesome, it put a hard ceiling on the stock price. VERA has way more upside potential in my opinion because flawless Phase 3 data means true open market expansion without any artificial price caps. If TRUTAKNA hits its targets this September, this binary catalyst could re rate the asset entirely. NFA.
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:30 AM
$VERA If flawless Phase 3 data drops in September, $VERA could rerate toward the $70 to $80 range. Odds heavily favor strong results since the FDA accelerated the eGFR timeline into Q3 2026, showing a massive vote of confidence for TRUTAKNA (atacicept) Massive sitting on a gold mine potential type binary catalyst ahead. NFA. $CRNX
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:14 AM
$VERA Trending
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:14 AM
$VERA $AMLX $MRNA
0 · Reply
grandefappuccino
grandefappuccino Aug. 23 at 11:42 PM
$VERA confused but here for it
0 · Reply
Takeprofit61
Takeprofit61 Aug. 23 at 11:25 PM
$VERA Positive divergence with a/c line
0 · Reply
PaulMacfarland845
PaulMacfarland845 Aug. 22 at 3:43 PM
$VERA $WFC $HONA $ALB $ACI VERA advances autoimmune therapies, Wells Fargo benefits from banking activity and net-interest trends, HONA remains speculative, Albemarle remains tied to lithium prices and battery demand, and Albertsons benefits from grocery spending. I'm watching clinical data, credit conditions, lithium prices, and consumer volumes.
0 · Reply
Takeprofit61
Takeprofit61 Aug. 21 at 5:41 PM
$VERA Positive divergence with A/C line
0 · Reply
Latest News on VERA
Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright

2026-08-17T10:15:28.000Z - 7 days ago

Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright

Vera Therapeutics price target raised to $84 from $78 at Raymond James

2026-08-11T12:55:26.000Z - 13 days ago

Vera Therapeutics price target raised to $84 from $78 at Raymond James

Vera Therapeutics price target lowered to $34 from $43 at Wedbush

2026-08-11T11:50:48.000Z - 13 days ago

Vera Therapeutics price target lowered to $34 from $43 at Wedbush

Vera Therapeutics price target lowered to $66 from $70 at BofA

2026-08-11T10:30:51.000Z - 13 days ago

Vera Therapeutics price target lowered to $66 from $70 at BofA

Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)

2026-08-10T21:05:19.000Z - 13 days ago

Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)

Vera Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 4:00 PM EDT - 13 days ago

Vera Therapeutics Earnings release: Q2 2026

Vera Therapeutics Quarterly report: Q2 2026

Aug 10, 2026, 4:00 PM EDT - 13 days ago

Vera Therapeutics Quarterly report: Q2 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2026, 4:05 PM EDT - 16 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed

2026-07-09T12:25:58.000Z - 6 weeks ago

Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed

KYTX

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Jul 9, 2026, 8:00 AM EDT - 6 weeks ago

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Vera Therapeutics price target raised to $76 from $56 at Guggenheim

2026-07-08T13:15:27.000Z - 6 weeks ago

Vera Therapeutics price target raised to $76 from $56 at Guggenheim

Vera Therapeutics price target raised to $78 from $73 at TD Cowen

2026-07-08T12:15:30.000Z - 6 weeks ago

Vera Therapeutics price target raised to $78 from $73 at TD Cowen

Vera Therapeutics price target raised to $43 from $35 at Wedbush

2026-07-08T11:56:10.000Z - 6 weeks ago

Vera Therapeutics price target raised to $43 from $35 at Wedbush

Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright

2026-07-08T10:30:23.000Z - 6 weeks ago

Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright

Vera Therapeutics Transcript: FDA announcement

Jul 7, 2026, 4:30 PM EDT - 6 weeks ago

Vera Therapeutics Transcript: FDA announcement

Vera Therapeutics Press release: FDA announcement

Jul 7, 2026, 4:30 PM EDT - 6 weeks ago

Vera Therapeutics Press release: FDA announcement

Vera Therapeutics price target raised to $70 from $65 at BofA

2026-07-07T18:10:10.000Z - 6 weeks ago

Vera Therapeutics price target raised to $70 from $65 at BofA

US FDA approves Vera's kidney disease drug

Jul 7, 2026, 12:42 PM EDT - 6 weeks ago

US FDA approves Vera's kidney disease drug

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

Jul 7, 2026, 12:37 PM EDT - 6 weeks ago

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

Vera Therapeutics Slides: Corporate presentation

Jul 7, 2026, 7:00 AM EDT - 6 weeks ago

Vera Therapeutics Slides: Corporate presentation

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

2026-06-02T16:27:12.000Z - 2 months ago

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

Raymond James sees unique buying opportunity in Vera after FDA alignment

2026-06-02T16:26:20.000Z - 2 months ago

Raymond James sees unique buying opportunity in Vera after FDA alignment

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics Transcript: AGM 2026

May 21, 2026, 11:00 AM EDT - 3 months ago

Vera Therapeutics Transcript: AGM 2026

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

2026-05-15T12:28:46.000Z - 3 months ago

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)

2026-05-07T20:08:52.000Z - 3 months ago

Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:30 AM EDT - 3 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

Vera Therapeutics Earnings release: Q1 2026

Vera Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

Vera Therapeutics Quarterly report: Q1 2026

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

May 4, 2026, 7:30 AM EDT - 4 months ago

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Vera Therapeutics Proxy statement: Proxy filing

Vera Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Vera Therapeutics Proxy statement: Proxy filing

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Mar 25, 2026, 7:30 AM EDT - 5 months ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

2026-03-10T23:05:13.000Z - 5 months ago

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

VRTX

Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA

2026-03-10T12:03:07.000Z - 5 months ago

Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA

VRTX

Vera Therapeutics appoints Hite to Board of Directors

2026-03-05T14:16:31.000Z - 6 months ago

Vera Therapeutics appoints Hite to Board of Directors

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Mar 5, 2026, 9:00 AM EST - 6 months ago

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 6 months ago

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Feb 26, 2026, 7:30 AM EST - 6 months ago

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Vera Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:30 AM EST - 6 months ago

Vera Therapeutics Annual report: Q4 2025

Vera Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 6 months ago

Vera Therapeutics Earnings release: Q4 2025

Vera Therapeutics to Participate at Upcoming Investor Conferences

Feb 24, 2026, 8:00 AM EST - 6 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Jan 28, 2026, 7:30 AM EST - 7 months ago

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Vera Therapeutics Slides: Corporate presentation

Jan 28, 2026, 7:00 AM EST - 7 months ago

Vera Therapeutics Slides: Corporate presentation

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 8 months ago

Vera Therapeutics Slides: Corporate presentation

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Jan 7, 2026, 7:30 AM EST - 8 months ago

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Wells Fargo sees short squeeze ahead: here are three stocks to play it

Jan 6, 2026, 2:31 PM EST - 8 months ago

Wells Fargo sees short squeeze ahead: here are three stocks to play it

HRI MTDR

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Dec 9, 2025, 8:57 PM EST - 9 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dec 8, 2025, 4:01 PM EST - 9 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 4:00 PM EST - 9 months ago

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:45 AM EST - 9 months ago

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Nov 26, 2025, 4:05 PM EST - 9 months ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 13, 2025, 1:30 PM EST - 10 months ago

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Nov 10, 2025, 7:29 AM EST - 10 months ago

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Nov 7, 2025, 6:27 PM EST - 10 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Vera Therapeutics Transcript: KOL Event

Nov 6, 2025, 4:30 PM EST - 10 months ago

Vera Therapeutics Transcript: KOL Event

Vera Therapeutics Press release: KOL Event

Nov 6, 2025, 4:30 PM EST - 10 months ago

Vera Therapeutics Press release: KOL Event

Vera Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 4:30 PM EST - 10 months ago

Vera Therapeutics Slides: Corporate Presentation

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Nov 6, 2025, 9:51 AM EST - 10 months ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:29 AM EST - 10 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Vera Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Vera Therapeutics Earnings release: Q3 2025

Vera Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Vera Therapeutics Quarterly report: Q3 2025

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Oct 17, 2025, 9:12 AM EDT - 11 months ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:10 AM EDT - 1 year ago

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Vera Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 12:30 PM EDT - 1 year ago

Vera Therapeutics Quarterly report: Q2 2025

Vera Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 12:30 PM EDT - 1 year ago

Vera Therapeutics Earnings release: Q2 2025

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:05 PM EDT - 1 year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 3:15 PM EDT - 1 year ago

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 1 year ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 3, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Vera Therapeutics Transcript: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Vera Therapeutics Press release: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Press release: Study Result

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Vera Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Quarterly report: Q1 2025

Vera Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Earnings release: Q1 2025

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:25 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics Annual report: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics Annual report: Q4 2024

Vera Therapeutics Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics Earnings release: Q4 2024

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Vera Therapeutics Slides: FY 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Slides: FY 2025

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 5, 2024, 7:55 AM EST - 1 year ago

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 9:30 AM EST - 1 year ago

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Vera Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics Quarterly report: Q3 2024

Vera Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics Earnings release: Q3 2024

Vera Therapeutics Transcript: Study Result

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Vera Therapeutics Slides: Study Result

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Slides: Study Result

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 26, 2024, 7:30 PM EDT - 1 year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Transcript: R&D Day 2024

Oct 2, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Transcript: R&D Day 2024

Vera Therapeutics Slides: FY 2024

Oct 2, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Slides: FY 2024

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 2 years ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Oct 2, 2024, 6:30 AM EDT - 2 years ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 9:10 AM EDT - 2 years ago

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

Sep 3, 2024, 7:49 AM EDT - 2 years ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Quarterly report: Q2 2024

Vera Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q2 2024

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 11, 2024, 4:01 PM EDT - 2 years ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics Slides: Corporate Presentation

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Slides: Corporate Presentation

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 28, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 25, 2024, 9:40 AM EDT - 2 years ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Vera Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Quarterly report: Q1 2024

Vera Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q1 2024

Vera Therapeutics Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Annual report: Q4 2023

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Annual report: Q4 2023

Vera Therapeutics Earnings release: Q4 2023

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q4 2023

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 20, 2024, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Mar 4, 2024, 2:10 PM EST - 2 years ago

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 28, 2024, 4:20 PM EST - 2 years ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Vera Therapeutics Slides: Corporate Presentation

Feb 14, 2024, 2:00 AM EST - 2 years ago

Vera Therapeutics Slides: Corporate Presentation

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 2, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Feb 1, 2024, 4:05 PM EST - 2 years ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 2 years ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Vera Therapeutics Transcript: R&D Day 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Transcript: R&D Day 2024

Vera Therapeutics Press release: FY 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Press release: FY 2024

Vera Therapeutics Slides: FY 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Slides: FY 2024

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 25, 2024, 6:30 AM EST - 2 years ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

AgnesGregory654
AgnesGregory654 Aug. 24 at 9:18 AM
$VERA $WFC $HONA $ALB $ACI VERA advances autoimmune therapies, Wells Fargo benefits from banking activity and net-interest trends, HONA remains speculative, Albemarle remains tied to lithium prices and battery demand, and Albertsons benefits from grocery spending. I'm watching clinical data, credit conditions, lithium prices, and consumer volumes.
0 · Reply
philosophernutz
philosophernutz Aug. 24 at 1:05 AM
$VERA we need the data to drop to get some real traction.
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:33 AM
$VERA And also, do not forget $CRNX because while that buyout at eighty five dollars cash was awesome, it put a hard ceiling on the stock price. VERA has way more upside potential in my opinion because flawless Phase 3 data means true open market expansion without any artificial price caps. If TRUTAKNA hits its targets this September, this binary catalyst could re rate the asset entirely. NFA.
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:30 AM
$VERA If flawless Phase 3 data drops in September, $VERA could rerate toward the $70 to $80 range. Odds heavily favor strong results since the FDA accelerated the eGFR timeline into Q3 2026, showing a massive vote of confidence for TRUTAKNA (atacicept) Massive sitting on a gold mine potential type binary catalyst ahead. NFA. $CRNX
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:14 AM
$VERA Trending
0 · Reply
Higherpattern
Higherpattern Aug. 24 at 12:14 AM
$VERA $AMLX $MRNA
0 · Reply
grandefappuccino
grandefappuccino Aug. 23 at 11:42 PM
$VERA confused but here for it
0 · Reply
Takeprofit61
Takeprofit61 Aug. 23 at 11:25 PM
$VERA Positive divergence with a/c line
0 · Reply
PaulMacfarland845
PaulMacfarland845 Aug. 22 at 3:43 PM
$VERA $WFC $HONA $ALB $ACI VERA advances autoimmune therapies, Wells Fargo benefits from banking activity and net-interest trends, HONA remains speculative, Albemarle remains tied to lithium prices and battery demand, and Albertsons benefits from grocery spending. I'm watching clinical data, credit conditions, lithium prices, and consumer volumes.
0 · Reply
Takeprofit61
Takeprofit61 Aug. 21 at 5:41 PM
$VERA Positive divergence with A/C line
0 · Reply
flamingojack
flamingojack Aug. 20 at 6:54 PM
$VERA smell that? That’s bearish desperation.
0 · Reply
CH_Expat
CH_Expat Aug. 20 at 4:35 PM
$MLYS $VERA Posting from June on the CRNX board. 3 weeks before booooom.
2 · Reply
greensmell
greensmell Aug. 20 at 2:25 PM
$VERA I'll stop posting here only out of respect to the fine gentleman @CH_Expat ..good luck to us all
1 · Reply
Valueforall
Valueforall Aug. 20 at 5:21 AM
$VERA Following @CH_Expat observation of certain equities being pinned, I have an AI model that I have fed significant hostorical content of biotechs and their price supression balance with fundamentals and relative performance against indexes. So this isnt AI slop but a dedicated machine with years of historical content about the universe of small cap tickers and stories about their ultimate M&A including many of the names talked about, CRNX, APLS, SLNO etc
2 · Reply
CH_Expat
CH_Expat Aug. 19 at 7:53 PM
$VERA XBI up 6%, we are red. Imagine you are long here and you are already down 20%. What a kick in the balls. You feel like shit. You feel like nothing in the world can move this stock. You get miserable and frustrated. And this is exactly where they want you to be.
1 · Reply
forprofit12
forprofit12 Aug. 19 at 4:20 PM
$VERA yes. This is my highest conviction stock now. There is a reason this is being suppressed.
1 · Reply
CH_Expat
CH_Expat Aug. 19 at 3:35 PM
$VERA Days like today are very important for whales to soak up more shares. XBI flying? Pin it flat or red on little volume to make retail and small funds bail. They do whatever they want. Increas/decrease ratio of bio funds in Q2 was 2:1. They are accumulating while we get depressed. Sit on your ass, add in the 20s if ever and wait it out.
1 · Reply
Merlintrader
Merlintrader Aug. 19 at 3:31 PM
$TVTX vs $VERA: The Business That Already Exists vs the Upside That Could Become Enormous https://www.merlintrader.com/tvtx-vs-vera-iga-nephropathy-stock-comparison/
1 · Reply
Higherpattern
Higherpattern Aug. 19 at 3:25 PM
$VERA is next IMO. 🚀 Massive short percentage + small float means this thing can go straight to $70 and keep rising from there. Don't miss out! Biotech is absolutely exploding right now and this is the next major play. You don't want to miss this one. Any day now Q3 data is dropping. Historical odds say 85% chance of positive data, but with recent reports, it's looking closer to 90%. Absolute gold mine here. Also adding $AMLX and $MRNA to my portfolio for the long term after their massive wins. BIOTECH SEASON BABY!
0 · Reply
CH_Expat
CH_Expat Aug. 19 at 2:23 PM
$VERA Added 800 for 32.15 USD. Love doing that on fake days when XBI is flying and my picks are flat or red.
0 · Reply
CH_Expat
CH_Expat Aug. 19 at 2:16 PM
$VERA Fake algo level here is 11/10. I like this, gives me CRNX and BPMC vibes.
0 · Reply
CH_Expat
CH_Expat Aug. 19 at 2:04 PM
$VERA Even on a day like today we manage to underperform XBI. Keep in mind it is all orchestrated from the whales to steal more shares. Institutional ownership grew further. We are just playballs.
0 · Reply